GgoogleIT first seen 16 h ago, last 16 h ago, peak #1

Sacituzumab govitecan shows promise in aggressive breast cancer case

Original: neoplasia

A medical journal report describes a patient with triple-negative breast cancer whose early bone recurrence resisted first-line chemotherapy but was treated with sacituzumab govitecan. The antibody-drug conjugate is drawing attention among oncologists as an option for hard-to-treat relapses, in Italy and beyond.

Why now: Interest in new treatment options for triple-negative breast cancer relapse, a particularly aggressive disease

sacituzumab govitecantriple-negative breast cancerRecenti Progressi in MedicinaItaly

Open on google →

Rank over time, top of the chart is #1. 3 snapshots from 16 h ago to 16 h ago.

Evidence

• Sacituzumab govitecan in paziente con recidiva ossea precoce di carcinoma mammario triplo negativo refrattario alla chemioterapia di prima linea · Recenti Progressi in Medicina

API: https://socialmediatrends-api.osmike.com/v1/trends/1235019